Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Denali Therapeutics Inc (DNLI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: DNLI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -34.63% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.00B USD | Price to earnings Ratio - | 1Y Target Price 36.62 |
Price to earnings Ratio - | 1Y Target Price 36.62 | ||
Volume (30-day avg) 1332610 | Beta 1.46 | 52 Weeks Range 12.05 - 33.33 | Updated Date 04/2/2025 |
52 Weeks Range 12.05 - 33.33 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.57 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -24.82% | Return on Equity (TTM) -37.4% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1001073155 | Price to Sales(TTM) 3643.65 |
Enterprise Value 1001073155 | Price to Sales(TTM) 3643.65 | ||
Enterprise Value to Revenue 2843.16 | Enterprise Value to EBITDA -8.66 | Shares Outstanding 145215008 | Shares Floating 131342965 |
Shares Outstanding 145215008 | Shares Floating 131342965 | ||
Percent Insiders 9.56 | Percent Institutions 90.92 |
Analyst Ratings
Rating 4.67 | Target Price 39.73 | Buy 4 | Strong Buy 13 |
Buy 4 | Strong Buy 13 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Denali Therapeutics Inc
Company Overview
History and Background
Denali Therapeutics Inc. was founded in 2015. It focuses on developing therapies for neurodegenerative diseases, addressing a significant unmet need in treating conditions like Alzheimer's and Parkinson's.
Core Business Areas
- Neurodegeneration Therapies: Denali develops small molecule and antibody therapies designed to cross the blood-brain barrier and address underlying causes of neurodegenerative diseases.
- Engineered Transport Vehicle (ETV) Technology: Denali's ETV technology is a key platform for delivering therapeutic proteins into the brain.
Leadership and Structure
Ryan Watts is the CEO. The company operates with a structure focused on research and development, clinical trials, and strategic partnerships.
Top Products and Market Share
Key Offerings
- Takeda Collaboration Programs: Denali has a collaboration with Takeda to develop therapies for neurodegenerative diseases. Revenue from this collaboration contributes significantly to Denali's financial performance. The competitors for this product are Ionis, Biogen, and Roche. Market share data is unavailable. Focus is on Alzheimer's and other dementias.
- SAR443820/DNL151 (ALS Program): SAR443820/DNL151 is being developed for amyotrophic lateral sclerosis (ALS) and is in clinical trials. Competitors for this product include Amylyx Pharmaceuticals, Biogen. Revenue from this is not yet available.
Market Dynamics
Industry Overview
The neurodegenerative disease therapeutics market is growing rapidly, driven by an aging population and increasing prevalence of diseases like Alzheimer's and Parkinson's. There's high unmet need and intense research activity.
Positioning
Denali is positioned as a leader in developing therapies that can cross the blood-brain barrier. Its ETV technology gives it a competitive advantage.
Total Addressable Market (TAM)
The TAM for neurodegenerative disease therapies is estimated to be in the tens of billions of dollars annually, with continued growth expected. Denali is positioned to capture a portion of this market with its innovative technologies.
Upturn SWOT Analysis
Strengths
- Proprietary ETV technology
- Strong partnerships with major pharmaceutical companies
- Experienced management team
- Focus on high unmet medical needs
Weaknesses
- High cash burn rate
- Reliance on clinical trial success
- Early stage development pipeline
- Dependence on partnerships for revenue
Opportunities
- Expansion of ETV technology to other disease areas
- Potential for breakthrough therapies for neurodegenerative diseases
- Growing market for neurodegenerative disease treatments
- Strategic acquisitions and collaborations
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- ABBV
- BIIB
- LLY
- ROCHE (ROG.SW)
Competitive Landscape
Denaliu2019s advantage lies in its blood-brain barrier technology; however, larger pharmaceutical firms possess extensive resources for drug development and commercialization.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by expanding its pipeline and securing partnerships with major pharmaceutical companies.
Future Projections: Future growth is projected to be strong if clinical trials are successful and new partnerships are established. Analyst expectations vary.
Recent Initiatives: Focus on advancing clinical programs, expanding the ETV technology platform, and exploring new partnerships.
Summary
Denali Therapeutics is a promising biotech company focused on neurodegenerative diseases with a novel drug delivery platform. While its reliance on clinical trials and partnerships present risks, its innovative technology and market opportunity create significant potential. Success hinges on positive clinical outcomes and strategic dealmaking to bolster long-term sustainability. The company needs to carefully manage its cash burn as it pursues clinical trial success.
Similar Companies
BIIB
Biogen Inc
BIIB
Biogen Inc
BLUE
Bluebird bio Inc
BLUE
Bluebird bio Inc
LLY
Eli Lilly and Company
LLY
Eli Lilly and Company
VRTX
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
Sources and Disclaimers
Data Sources:
- Denali Therapeutics Investor Relations
- Analyst reports
- Market research reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market share data can be difficult to extract from public sources. The user should seek professional financial advice before making any investment decisions. Financial data is based on the most recently available information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Denali Therapeutics Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2017-12-08 | Co-Founder, President, CEO & Director Dr. Ryan J. Watts Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 422 | |
Full time employees 422 | |||
Denali Therapeutics Inc., discovers, develops, and delivers barrier-crossing therapeutics for neurodegenerative, lysosomal, and other serious diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; DNL921 Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.